Universität zu Köln

Waidmann, Oliver, Pelzer, Uwe ORCID: 0000-0001-9213-2737, Boeck, Stefan and Waldschmidt, Dirk-Thomas (2018). Sequence therapy in metastatic pancreatic cancer. Z. Gastroent., 56 (6). S. 578 - 583. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-7803

Full text not available from this repository.

Abstract

Pancreatic cancer is one of the most lethal cancer diseases. For years, gemcitabine has been the standard of care and the only therapeutic option in patients with metastatic pancreatic cancer. Within the last years, new combination therapies have been established for first-line treatment, which significantly improve overall survival in comparison to gemcitabine monotherapy. Furthermore, new second-line therapies have been identified, which significantly improve overall survival. The current manuscript summarizes briefly standard of care first- and second-line chemotherapies and discusses possible treatment sequences.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Waidmann, Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED Pelzer, Uwe UNSPECIFIED orcid.org/0000-0001-9213-2737 UNSPECIFIED Boeck, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Waldschmidt, Dirk-Thomas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-184929
DOI:	10.1055/a-0581-5640
Journal or Publication Title:	Z. Gastroent.
Volume:	56
Number:	6
Page Range:	S. 578 - 583
Date:	2018
Publisher:	GEORG THIEME VERLAG KG
Place of Publication:	STUTTGART
ISSN:	1439-7803
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language NAB-PACLITAXEL PLUS; 2ND-LINE THERAPY; FOLFIRINOX FAILURE; FOLINIC ACID; OPEN-LABEL; PHASE-II; GEMCITABINE; MULTICENTER; ADENOCARCINOMA; TRIAL Multiple languages Gastroenterology & Hepatology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/18492